参考文献：
1.de Angelis, C., Drazen, J.M., Frizelle, F.A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A.J., Schroeder, T.V., Sox, H.C., Van Der Weyden, M.B., 2004. Clinical trial registration: a statement from the international committee of medical journal editors. N. Engl. J. Med. 351, 1250–1251.
2.Brassington, I., 2017. The ethics of reporting all the results of clinical trials. Br. Med. Bull. 121 (1), 19–29.
3.EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016. Guidance on the scientific requirements for health claims related to the immune system, the gastrointestinal tract and defence against pathogenic microorganisms, 2016 EFSA J. 14 (1), 4369, 23.
4.FAO/WHO, 2002. Guidelines for the Evaluation of Probiotics in Food.https://www.who .int/foodsafety/fs_management/en/probiotic_guidelines.pdf.
5.Gibson, G.R., Brummer, R.J., Isolauri, E., Lochs, H., Morelli, L., Ockhuizen, T., Rowland, I.R., Schrezenmeir, J., Stanton, C., Verbeke, K., 2011. The design of probiotic studies to substantiate health claims. Gut Microb. 2 (5), 299–305.
6.Goldin, B.R., Gualtieri, L.J., Moore, R.P., 1996. The effect of Lactobacillus GG on the initiation and promotion of DMH-induced intestinal tumors in the rat. Nutr. Canc. 25, 197–204. Gorbach, S.L., 1996. The discovery of Lactobacillus GG. Nutr. Today 31, 2S–5S.
7.Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C., Sanders, M.E., 2014. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotics. Nat. Rev. Gastroenterol. Hepatol. 11, 506–514.
8.Johnson, R.T., Dickersin, K., 2007 Nov. Publication bias against negative results from clinical trials: three of the seven deadly sins. Nat. Clin. Pract. Neurol. 3 (11), 590–591.
9.Jungersen, M., Wind, A., Johansen, E., Christensen, J.E., Stuer-Lauridsen, B., Eskesen, D., 2014. The science behind the probiotic strain Bifidobacterium animalis subsp. lactis BB-12(?). Microorganisms 2 (2), 92–110.
10.Mora, D., Filardi, R., Arioli, S., Boeren, S., Aalvink, S., de Vos, W.M., 2019. Development of omics-based protocols for the microbiological characterization of multi-strain formulations marketed as probiotics: the case of VSL#3. Microb. Biotechnol.
11.Public Law, 1997. 105–115: Food and Drug Administration Modernization Act of 1997. Adopted November 21, 1997. https://www.gpo.gov/fdsys/pkg/PLAW-105publ115/ pdf/PLAW-105publ115.pdf. (Accessed August 2019).
12.Rijkers, G., Andriessen, Q., van Overveld, F.J., 2019. Death and the Miser: microbiota regulate the outcome of checkpoint inhibition immunotherapy. Expet Rev. Anticancer Ther.
13.Singh, S., Stroud, A.M., Holubar, S.D., Sandborn, W.J., Pardi, D.S., 2015. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst. Rev. (11), CD001176

稿源：(热心肠先生)

【】网址：http://www.shadafang.com/c/hn1022aK402020.html

标题：注册|全球益生菌临床试验分析：哪种菌最火？哪种病最热？( 五 )